Peroxisome Proliferator-Activated Receptor Agonists and Bladder Cancer: Lessons from Animal Studies-Reference-Cited by-同舟云学术

Peroxisome Proliferator-Activated Receptor Agonists and Bladder Cancer: Lessons from Animal Studies

Published:2012-10 Issue:4 Volume:30 Page:368-402
ISSN:1059-0501
Container-title:Journal of Environmental Science and Health, Part C
language:en
Short-container-title:Journal of Environmental Science and Health, Part C

Author:

TSENG CHIN-HSIAO,TSENG FARN-HSUAN

Publisher

Informa UK Limited

Subject

Cancer Research,Health, Toxicology and Mutagenesis

Link

http://www.tandfonline.com/doi/pdf/10.1080/10590501.2012.735519

Reference90 articles.

1. El-Hage , J . Peroxisome proliferation-activated receptor agonists: carcinogenicity findings and regulatory recommendations . In International Atherosclerosis Society Symposium on PPAR, Monte Carlo ,

2. Effects of Pioglitazone, a Peroxisome Proliferator–Activated Receptor Gamma Agonist, on the Urine and Urothelium of the Rat

3. The Mechanisms of Action of PPARs

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan;Cancers;2023-08-26

2. Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients;Pharmaceuticals;2023-05-01

3. Pioglitazone, Bladder Cancer, and the Presumption of Innocence;Current Drug Safety;2022-11

4. Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis;BMC Cancer;2022-05-18

5. Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study;International Journal of Chronic Obstructive Pulmonary Disease;2022-02